# Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation

> **NCT02431988** · PHASE1 · COMPLETED · sponsor: **University College, London** · enrollment: 10 (actual)

## Conditions studied

- Diffuse Large B-Cell Lymphoma

## Interventions

- **PROCEDURE:** Leukapheresis
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **BIOLOGICAL:** CAR19 T-Cells

## Key facts

- **NCT ID:** NCT02431988
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06
- **Primary completion:** 2020-02-02
- **Final completion:** 2022-03-21
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2023-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02431988

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02431988, "Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02431988. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*